Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

Komal Jhaveri,Valentina Boni,Joohyuk Sohn,Rafael Villanueva-Vásquez,Aditya Bardia,Peter Schmid,Elgene Lim,Jaymin M. Patel,José Alejandro Pérez Fidalgo,Sherene Loi,Seock-Ah Im,Smita Kshirsagar,Mary Gates,John Bond,Jennifer Eng-Wong,Ching-Wei Chang,Nicholas C. Turner,Elena López-Miranda,Laura Garcia-Estevez,Meritxell Bellet

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).

2021

1017Background: Targeting ER activity and/or E synthesis is a mainstay of ER+ BC treatment, but many pts relapse during/after adjuvant endocrine therapy (ET) or develop resistance via ESR1 mutation...

Keywords:

Cancer research
Adjuvant
locally advanced
in patient
Metastatic breast cancer
single agent
Estrogen receptor
Medicine
Estrogen receptor alpha
HER2 negative

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations